Newspaper publication pertaining to Unaudited Financial Results for the quarter and nine months ended December 31, 2025.
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech has published its unaudited financial results for the quarter and nine months ended December 31, 2025 in Business Standard and Sakal newspapers, as required under SEBI Listing Regulations. On a consolidated basis, Q3 FY26 revenue from operations stood at Rs. 14,047.77 lakhs (down from Rs. 15,869.61 lakhs in Q3 FY25), while net profit after tax came in at Rs. 1,202.31 lakhs (down sharply from Rs. 3,789.01 lakhs in Q3 FY25). For the nine-month period, consolidated revenue grew to Rs. 42,116.73 lakhs (vs Rs. 33,755.38 lakhs) and net profit rose to Rs. 5,165.40 lakhs (vs Rs. 4,307.94 lakhs). Consolidated basic EPS for 9M FY26 was Rs. 18.58, up from Rs. 14.67 in the prior year period. On a standalone basis, Q3 revenue was Rs. 11,767.39 lakhs with net profit of Rs. 1,175.92 lakhs.
Q3 FY26 showed a notable year-on-year decline in both revenue and profit, which may weigh on short-term investor sentiment. However, the strong cumulative nine-month growth in revenue (~25%) and profit (~20%) indicates overall healthy performance for the year so far. The filing itself is a routine regulatory publication and does not signal any new corporate action.